Understand the source comparison
Semax Amidate Stroke Recovery: Research Grade Comparison
Primary Mechanism MC4R agonist → BDNF upregulation Neurotrophin mixture (undefined composition) CNTF mimetic → STAT3 activation Semax offers single-receptor specificity with defined pathway activation Therapeutic Window 0–6 hours post-ischemia 0–12 hours 0–24
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- MC4R agonist → BDNF upregulation
- Neurotrophin mixture (undefined composition)
- CNTF mimetic → STAT3 activation
- Semax offers single-receptor specificity with defined pathway activation
- Therapeutic Window
- 0–6 hours post-ischemia
- 0–12 hours
- 0–24 hours
- Narrower window but higher acute efficacy
- BBB Penetration
- Intranasal bypasses BBB; SC uses receptor-mediated transcytosis
- Direct CNS injection required
- Crosses BBB via LAT1 transporter
- Intranasal route is non-invasive advantage
- Half-Life
- 90–120 minutes (amidate-modified)
- 4–6 hours (protein fraction dependent)
- 45–60 minutes
- Amidate modification extends durability vs unmodified peptides
- Infarct Reduction (Preclinical)
- 30–40% at 3hr administration
- 25–35% at 6hr administration
- 20–30% at 12hr administration
- Comparable efficacy but earlier intervention required
- Oxidative Stress Reduction
- Nrf2 activation → 35% MDA reduction
- Mixed antioxidant effects (mechanism unclear)
- Minimal direct antioxidant activity
- Defined Nrf2 pathway is mechanistic advantage